Differential response to Lenalidomide from WT and RUNX1-KO MDS-L del(5q) cells. Differential response to Lenalidomide from WT and RUNX1-KO MDS-L del(5q) cells

We used CRISPR/Cas9 system to generate WT Control and RUNX1-KO MDS-L cells isolated as single clones from the parental MDS-L cell line. We have observed that RUNX1-KO MDS-L cells are resistant to Lenalidomide-induced cell death compared to WT Control MDS-L cells We have treated WT and RUNX1-KO MDS-L cells with 1µM Lenalidomide for 24h or 72h and performed expression analysis Overall design: The experiment consists in eight groups in total. Each group was analyzed with three technical replicates. The groups (per timepoint) are as follows: MDS-L WT DMSO; MDS-L WT LEN; MDS-L KO DMSO; MDS-L KO LEN. We then compared the transcriptional response to LEN within each genotype (MDS-L WT or MDS-L RUNX1-KO).Genes with padj<0.05 we identified as differentially expressed.